ClinicalTrials.gg
CompletedNCT00819780Updated Dec 6, 2022Results posted

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

A Phase 2 interventional study of Panitumumab and Bevacizumab in Colon Cancer, Colorectal Cancer and Rectal Cancer, sponsored by Amgen. Completed at 95 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-06.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing panitumumab in Colonic Neoplasms — 1 open to participants now, 2 under way, 1 of them phase 3. Panitumumab · Colonic Neoplasms.

Enrollment
6th of 21
285 · median 116
Started
2009
the only one that year
Phase 2
15 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
6 of 22
Amgen

Among the 22 studies testing panitumumab in Colonic Neoplasms, this one is the 6th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2009, is one of 15 in phase 2, and was the 11th registered.

Colonic Neoplasms

2,456 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

1 of the 22 studies testing panitumumab in Colonic Neoplasms is open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 204 (62%) set no upper age limit and 71 (22%) stop at 75 or younger; 19 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing panitumumab in Colonic Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the treatment effect on progression-free survival (PFS) of panitumumab relative to bevacizumab in combination with mFOLFOX6 chemotherapy as first-line therapy in patients with tumors expressing wild-type KRAS, unresectable mCRC.

03

Conditions studied

  • Colon Cancer
  • Colorectal Cancer
  • Rectal Cancer
  • Metastatic Colorectal Cancer

Keywords

  • Colon Cancer
  • Colorectal Cancer
  • Rectal Cancer
  • Panitumumab
  • Vectibix
  • modified FOLFOX 6
  • mFOLFOX 6
  • FOLFOX
  • Bevacizumab
  • Avastin
  • First-Line
  • metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically-confirmed adenocarcinoma of the colon or rectum in patients with unresectable (M1) disease
  • Patients with at least 1 uni-dimensionally of at least 10 mm per modified (RECIST) guidelines
  • Wild-type KRAS tumor status confirmed by an Amgen approved central laboratory or an experienced laboratory (local laboratory) per local regulatory guidelines using a validated test method
  • (ECOG) score of 0 or 1
  • Men or women 18 years of age or older
  • Adequate hematologic, renal, hepatic, metabolic, and coagulation function

Exclusion criteria

Exclusion Criteria:

  • History of prior or concurrent central nervous system (CNS)
  • Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma
  • cardiac disease
  • Clinically significant peripheral sensory neuropathy
  • Active inflammatory bowel disease
  • Recent gastroduodenal ulcer to be active or uncontrolled
  • History of interstitial lung disease
  • Recent pulmonary embolism, deep vein thrombosis, or other significant venous event
  • Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy
  • Recent major surgical procedure, open , or significant traumatic injury not yet recovered from prior major surgery.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
285 participants (actual)

Study arms

  • Experimental
    Panitumumab Plus mFOLFOX6

    Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU) (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.

    Drug: Panitumumab · Drug: mFOLFOX6

  • Active comparator
    Bevacizumab Plus mFOLFOX6

    Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.

    Drug: Bevacizumab · Drug: mFOLFOX6

Interventions

  • Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).

    Also known as: Vectibix

  • Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).

    Also known as: Avastin

  • DrugmFOLFOX6

    mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  2. Percentage of Participants With an Objective Response

    Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  3. Duration of Response

    For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  4. Time to Disease Progression

    Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  5. Time to Initial Objective Response

    For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  6. Resection Rate

    The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  7. Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)

    PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  8. Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

    PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  9. Overall Survival in Participants With Wild-type RAS

    Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  10. Overall Survival in Participants With Wild-type RAS / BRAF

    Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  11. Percentage of Participants With an Objective Response for Participants With Wild-type RAS

    Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  12. Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF

    Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

    Time frame: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

  13. Number of Participants With Adverse Events (AEs)

    Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug.

    Time frame: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.

07

Results

Posted Aug 6, 2014

Participant flow

First patient was enrolled on 24 April 2009; last patient was enrolled on 09 December 2011.

Participant flow — Overall Study
MilestonePanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Started142143
Received study treatment139139
Completed114122
Not completed2821
Withdrew: Did not receive study drug34
Withdrew: Still in treatment2517

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Progression-free Survival (PFS)10.9 (9.4 to 13.0)10.1 (9.0 to 12.6)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.3531 · Cox proportional hazard: 0.871 · 95% CI 0.651 to 1.166A hazard ratio \< 1.0 favors panitumumab
SecondaryOverall Survival

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Overall Survival
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Overall SurvivalNA (28.8 to NA)25.4 (22.9 to 29.5)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.1386 · Cox proportional hazard: 0.723 · 95% CI 0.470 to 1.111A hazard ratio \< 1.0 favors panitumumab
SecondaryPercentage of Participants With an Objective Response

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Percentage of Participants With an Objective Response57.75 (49.18 to 65.98)53.52 (44.97 to 61.93)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified exact test · p = 0.5497 · Odds ratio (or): 1.19 · 95% CI 0.72 to 1.95The odds ratio is defined as the odds of having an objective response in the panitumumab plus mFOLFOX6 arm relative to the odds in the bevacizumab plus mFOLFOX6 arm.
SecondaryDuration of Response

For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Duration of Response
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Duration of Response10.0 (8.4 to 12.9)9.0 (7.4 to 9.5)
SecondaryTime to Disease Progression

Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Time to Disease Progression
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Time to Disease Progression11.0 (9.7 to 13.1)11.1 (9.3 to 12.7)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.3861 · Cox proportional hazard: 0.874 · 95% CI 0.645 to 1.185A hazard ratio \< 1.0 favors panitumumab
SecondaryTime to Initial Objective Response

For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Time to Initial Objective Response
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Time to Initial Objective Response1.8 (1.7 to 2.3)1.9 (1.7 to 3.7)
SecondaryResection Rate

The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Number · percentage of participants
Resection Rate
percentage of participantsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Resection Rate12.68 (7.69 to 19.29)11.19 (6.53 to 17.53)
SecondaryProgression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)13.0 (10.9 to 15.1)9.5 (9.0 to 12.7)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.0286 · Cox proportional hazard: 0.651 · 95% CI 0.444 to 0.956A hazard ratio \< 1.0 favors panitumumab
SecondaryProgression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)13.1 (10.9 to 15.8)9.7 (7.9 to 12.7)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.0083 · Cox proportional hazard: 0.579 · 95% CI 0.386 to 0.869A hazard ratio \< 1.0 favors panitumumab
SecondaryOverall Survival in Participants With Wild-type RAS

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Overall Survival in Participants With Wild-type RAS
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Overall Survival in Participants With Wild-type RASNA (28.8 to NA)29.0 (24.3 to NA)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.0934 · Cox proportional hazard: 0.606 · 95% CI 0.337 to 1.088A hazard ratio \< 1.0 favors panitumumab
SecondaryOverall Survival in Participants With Wild-type RAS / BRAF

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Median · months
Overall Survival in Participants With Wild-type RAS / BRAF
monthsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Overall Survival in Participants With Wild-type RAS / BRAFNA (NA to NA)29.0 (24.3 to NA)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified Cox proportional hazards · p = 0.0235 · Cox proportional hazard: 0.465 · 95% CI 0.239 to 0.902A hazard ratio \< 1.0 favors panitumumab
SecondaryPercentage of Participants With an Objective Response for Participants With Wild-type RAS

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response for Participants With Wild-type RAS
percentage of participantsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Percentage of Participants With an Objective Response for Participants With Wild-type RAS63.64 (52.69 to 73.63)60.49 (49.01 to 71.19)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified exact test · p = 0.9426 · Odds ratio (or): 1.08 · 95% CI 0.55 to 2.12The odds ratio is defined as the odds of having an objective response in the panitumumab plus mFOLFOX6 arm relative to the odds in the bevacizumab plus mFOLFOX6 arm.
SecondaryPercentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

Time frame:
From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF
percentage of participantsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF63.64 (51.88 to 74.30)61.54 (49.83 to 72.34)
Statistical analysis
  • Panitumumab Plus mFOLFOX6 vs Bevacizumab Plus mFOLFOX6 · Stratified exact test · p = 1.0000 · Odds ratio (or): 1.05 · 95% CI 0.52 to 2.15The odds ratio is defined as the odds of having an objective response in the panitumumab plus mFOLFOX6 arm relative to the odds in the bevacizumab plus mFOLFOX6 arm.
SecondaryNumber of Participants With Adverse Events (AEs)

Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug.

Time frame:
The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
Any adverse event (AE)139139
AE with worst grade of 38878
AE with worst grade of 43128
AE with worst grade of 579
Serious adverse event (SAE)6153
AE leading to discontinuation of study drug3437
Any treatment-related adverse event (TRAE)138136
Treatment-related AE with worst grade of 39277
Treatment-related AE with worst grade of 42425
Treatment-related AE with worst grade of 532
Serious treatment-related adverse event3728
TRAE leading to discontinuation of study drug2829

Adverse events

Collected over The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus mFOLFOX6—61/139 (43.9%)139/139 (100%)
Bevacizumab Plus mFOLFOX6—53/139 (38.1%)139/139 (100%)
Most frequent serious events
Showing 10 of 98
Most frequent serious events
EventPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
DiarrhoeaGastrointestinal disorders9/1391/139
Pulmonary embolismRespiratory, thoracic and mediastinal disorders7/1396/139
PyrexiaGeneral disorders2/1394/139
SyncopeNervous system disorders0/1394/139
Deep vein thrombosisVascular disorders4/1394/139
Febrile neutropeniaBlood and lymphatic system disorders3/1393/139
IleusGastrointestinal disorders1/1393/139
PneumoniaInfections and infestations2/1393/139
SepsisInfections and infestations3/1392/139
DehydrationMetabolism and nutrition disorders3/1390/139
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPanitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6
RashSkin and subcutaneous tissue disorders86/1399/139
DiarrhoeaGastrointestinal disorders84/13984/139
NauseaGastrointestinal disorders75/13983/139
NeutropeniaBlood and lymphatic system disorders63/13966/139
FatigueGeneral disorders50/13965/139
HypomagnesaemiaMetabolism and nutrition disorders57/1399/139
Decreased appetiteMetabolism and nutrition disorders56/13944/139
Dry skinSkin and subcutaneous tissue disorders53/13912/139
AstheniaGeneral disorders50/13944/139
Mucosal inflammationGeneral disorders49/13921/139

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6Total
Mean61.6 ± 10.460.5 ± 9.861.0 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6Total
Female5647103
Male8696182
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Panitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6Total
White or Caucasian131127258
Black or African American9615
Hispanic or Latino257
Asian044
Japanese011
Prior Adjuvant Oxaliplatin Therapy
Prior Adjuvant Oxaliplatin Therapy(participants)Panitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6Total
Yes141428
No128129257
RAS and BRAF Mutation Status
RAS and BRAF Mutation Status(participants)Panitumumab Plus mFOLFOX6Bevacizumab Plus mFOLFOX6Total
BRAF wild-type103108211
RAS Wild-type8882170
RAS/BRAF wild-type7779156
Testing not performed131831
Sample acceptance failure8715
08

Study locations

95 sites
  • Research Site
    Birmingham, Alabama 35205, United States
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Berkeley, California 94704, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Burbank, California 91505, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    La Verne, California 91750, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Riverside, California 92501, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Stamford, Connecticut 06902, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Boynton Beach, Florida 33435, United States
  • Research Site
    Coral Springs, Florida 33065, United States
  • Research Site
    Daytona Beach, Florida 32114, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Lake Worth, Florida 33467, United States
  • Research Site
    Alpharetta, Georgia 30005, United States
  • Research Site
    Augusta, Georgia 30901, United States
  • Research Site
    Savannah, Georgia 31405, United States
  • Research Site
    Post Falls, Idaho 83854, United States
  • Research Site
    Gurnee, Illinois 60031, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Indianapolis, Indiana 46237, United States
  • Research Site
    Overland Park, Kansas 66210, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Danville, Kentucky 40422, United States
  • Research Site
    Hazard, Kentucky 41701, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    Baltimore, Maryland 21204, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Boston, Massachusetts 02111, United States
  • Research Site
    Kalamazoo, Michigan 49048, United States
  • Research Site
    Lambertville, Michigan 48144, United States
  • Research Site
    Lansing, Michigan 48912, United States
  • Research Site
    Mountain Lakes, New Jersey 07046, United States
  • Research Site
    Sparta, New Jersey 07871, United States
  • Research Site
    Albuquerque, New Mexico 87131, United States
  • Research Site
    Buffalo, New York 14215, United States
  • Research Site
    East Setauket, New York 11733, United States
  • Research Site
    Staten Island, New York 10301, United States
  • Research Site
    Huntersville, North Carolina 28078, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Akron, Ohio 44304, United States
  • Research Site
    Columbus, Ohio 43228, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Mount Pleasant, South Carolina 29464, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Austin, Texas 78759, United States
  • Research Site
    Corpus Christi, Texas 78463, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Round Rock, Texas 78665, United States
  • Research Site
    Temple, Texas 76508, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    White River Junction, Vermont 05009, United States
  • Research Site
    Chesapeake, Virginia 23320, United States
  • Research Site
    Newport News, Virginia 23601, United States
  • Research Site
    Newport News, Virginia 23606, United States
  • Research Site
    Spokane, Washington 99218, United States
  • Research Site
    Vancouver, Washington 98684, United States
  • Research Site
    Charleroi, 6000, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Libramont, 6800, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Calgary, Alberta T2N 4N2, Canada
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
  • Research Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Research Site
    Montreal, Quebec H2X 3J4, Canada
  • Research Site
    Quebec, G1R 2J6, Canada
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Bielefeld, 33611, Germany
  • Research Site
    Magdeburg, 39104, Germany
  • Research Site
    München, 81737, Germany
  • Research Site
    München, 81925, Germany
  • Research Site
    Passau, 94032, Germany
  • Research Site
    Regensburg, 93049, Germany
  • Research Site
    Würzburg, 97070, Germany
  • Research Site
    Alba (CN), 12051, Italy
  • Research Site
    Fano, 61032, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Mantova, 46100, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    Varese, 21100, Italy
  • Research Site
    Málaga, AndalucÃ-a 29010, Spain
  • Research Site
    Santander, Cantabria 39008, Spain
  • Research Site
    Sabadell, Cataluña 08208, Spain
  • Research Site
    Elche, Comunidad 03203, Spain
  • Research Site
    A Coruña, Galicia 15006, Spain
  • Research Site
    San Sebastián De Los Reyes, Madrid 28702, Spain
09

References and documents

Publications

  • Rivera F, Karthaus M, Hecht JR, Sevilla I, Forget F, Fasola G, Canon JL, Guan X, Demonty G, Schwartzberg LS. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis. 2017 Aug;32(8):1179-1190. doi: 10.1007/s00384-017-2800-1. Epub 2017 Apr 19. PubMed 28424871 ↗
  • Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31. PubMed 24687833 ↗
  • Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119. PubMed 28449055 ↗
  • Heinemann V, Rivera F, O'Neil BH, Stintzing S, Koukakis R, Terwey JH, Douillard JY. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2016 Nov;67:11-20. doi: 10.1016/j.ejca.2016.07.019. Epub 2016 Sep 1. PubMed 27592068 ↗
  • Modest DP, Rivera F, Bachet JB, de Braud F, Pietrantonio F, Koukakis R, Demonty G, Douillard JY. Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials. Int J Cancer. 2019 Jul 15;145(2):576-585. doi: 10.1002/ijc.32110. Epub 2019 Jan 24. PubMed 30614531 ↗
  • Peeters M, Forget F, Karthaus M, Valladares-Ayerbes M, Zaniboni A, Demonty G, Guan X, Rivera F. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. ESMO Open. 2018 Feb 24;3(2):e000297. doi: 10.1136/esmoopen-2017-000297. eCollection 2018. PubMed 29531837 ↗
  • Taieb J, Geissler M, Rivera F, Karthaus M, Wilson R, Loupakis F, Price T, Tracy M, Burdon P, Peeters M. Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clin Colorectal Cancer. 2019 Dec;18(4):245-256.e5. doi: 10.1016/j.clcc.2019.07.009. Epub 2019 Jul 29. PubMed 31515083 ↗
  • Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. J Cancer Res Clin Oncol. 2018 Feb;144(2):321-335. doi: 10.1007/s00432-017-2534-z. Epub 2017 Oct 28. Erratum In: J Cancer Res Clin Oncol. 2018 Apr;144(4):795-797. doi: 10.1007/s00432-018-2591-y. PubMed 29080924 ↗
  • Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, Andre T, Peeters M. Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies. Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8. PubMed 29627309 ↗
  • Peeters M, Price T, Taieb J, Geissler M, Rivera F, Canon JL, Pentheroudakis G, Koukakis R, Burdon P, Siena S. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018 Aug;119(3):303-312. doi: 10.1038/s41416-018-0165-z. Epub 2018 Jul 17. PubMed 30013091 ↗
  • Sartore-Bianchi A, Garcia-Alfonso P, Geissler M, Kohne CH, Peeters M, Price T, Valladares-Ayerbes M, Zhang Y, Burdon P, Taieb J, Modest DP. Relationships Between Kohne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2021 Dec;20(4):305-313. doi: 10.1016/j.clcc.2021.05.007. Epub 2021 May 25. PubMed 34172397 ↗
  • Peeters M, Kafatos G, Taylor A, Gastanaga VM, Oliner KS, Hechmati G, Terwey JH, van Krieken JH. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. Eur J Cancer. 2015 Sep;51(13):1704-13. doi: 10.1016/j.ejca.2015.05.017. Epub 2015 Jun 3. PubMed 26049686 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in May 2012, 37 months.

Results were first posted in Aug 2014, 2 years 2 months after primary completion.

Of 136 phase 2 interventional studies under Colonic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2008
First posted
Jan 9, 2009
StartActual
Apr 24, 2009
Primary completionActual
May 30, 2012
CompletionActual
Jul 7, 2016
Results first posted
Aug 6, 2014
Last update
Dec 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00819780
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 9, 2009
Start date
Apr 24, 2009
Primary completion
May 30, 2012
Completion
Jul 7, 2016
Results posted
Aug 6, 2014
Last update
Dec 6, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion